In contrast, genetically indexed inhibition of TNF-TNFR1 signaling was predicted to reduce the risk of Crohn disease (OR 0.75; 95% CI 0.65–0.86) and ulcerative colitis (OR 0.84; 95% CI 0.74–0.97) and increase the risk of multiple sclerosis (OR 1.57; 95% CI 1.36–1.81), as expected. Here, TNF is linked to Crohn disease.